An algorithm for tailoring pharmacotherapy for smoking cessation: results from a Delphi panel of international experts

P Bader, P McDonald, P Selby, P Bader, P McDonald, P Selby

Abstract

Background: Evidence-based smoking cessation guidelines recommend nicotine replacement therapy (NRT), bupropion SR and varenicline as first-line therapy in combination with behavioural interventions. However, there are limited data to guide clinicians in recommending one form over another, using combinations, or matching individual smokers to particular forms.

Objective: To develop decision rules for clinicians to guide differential prescribing practices and tailoring of pharmacotherapy for smoking cessation.

Methods: A Delphi approach was used to build consensus among a panel of 37 international experts from various health disciplines. Through an iterative process, panellists responded to three rounds of questionnaires. Participants identified and ranked "best practices" used by them to tailor pharmacotherapy to aid smoking cessation. An independent panel of 10 experts provided cross-validation of findings.

Results: There was a 100% response rate to all three rounds. A high level of consensus was achieved in determining the most important priorities: (1) factors to consider in prescribing pharmacotherapy: evidence, patient preference, patient experience; (2) combinations based on: failed attempt with monotherapy, patients with breakthrough cravings, level of tobacco dependence; (3) specific combinations, main categories: (a) two or more forms of NRT, (b) bupropion + form of NRT; (4) specific combinations, subcategories: (1a) patch + gum, (1b) patch + inhaler, (1c) patch + lozenge; (2a) bupropion + patch, (2b) bupropion + gum; (5) impact of comorbidities on selection of pharmacotherapy: contraindications, specific pharmacotherapy useful for certain comorbidities, dual purpose medications; (6) frequency of monitoring determined by patient needs and type of pharmacotherapy.

Conclusion: An algorithm and guide were developed to assist clinicians in prescribing pharmacotherapy for smoking cessation. There appears to be good justification for "off-label" use such as higher doses of NRT or combination therapy in certain circumstances. This practical tool reflects best evidence to date of experts in tobacco cessation.

Conflict of interest statement

Competing interests: PS has received funds from Schering Canada to provide buprenorphine training (2000); he is a paid consultant and advisory board member, Pfizer Consumer Health Care Canada, Johnson and Johnson Consumer Health Care, Pfizer Inc, Sanofi-Synthelabo, Canada, GSK, Canada; Genpharm and Prempharm, Canada, CTI.

Figures

Figure 1. Algorithm for tailoring pharmacotherapy for…
Figure 1. Algorithm for tailoring pharmacotherapy for smoking cessation*†

References

    1. Curry SJ, Sporer AK, Pugach O, et al. Use of tobacco cessation treatments among young adult smokers: 2005 national health interview survey. Am J Public Health 2007;97:1464–9
    1. Rigotti NA. Increasing smoking cessation at the population level: thinking outside the box. J Public Health Management Practice 2006;12:3–5
    1. Fiore MC, Bailey WC, Cohen SJ, et al. Treating tobacco use and dependence: a clinical practice guideline Rockville, MD: US Department of Health and Human Services, 2000; AHRQ Publication No 00-0032
    1. Le Foll B, Melihan-Cheinin Rostoker G, et al. Smoking cessation guidelines: evidence-based recommendations of the French health products safety agency. Eur Psychiatry 2005;20:431–41
    1. National Health Committee Guidelines for smoking cessation. Revised 2002. Wellington: New Zealand Ministry of Health, 2002. Available online: . (Accessed 8 March 2008.)
    1. Royal Australian College of General Practitioners Guidelines for preventive activities in general practice. Aust Fam Phys. 2002. Special issue.
    1. Raw M, McNeill A, West R. Smoking cessation guidelines for health professionals. A guide to effective smoking cessation interventions for the public health system. Thorax 1998;53(suppl 5):S1–S38
    1. West R, McNeill A, Raw M. Smoking cessation guidelines for health professionals: an update. Thorax 2000;55:987–99
    1. Gonzales D, Rennard SI, Nides M, et al. Varenicline, an a4B2 nicotinic acetylcholine receptor partial agonist, vs sustained-release bupropion and placebo for smoking cessation. JAMA 2006;296:47–55
    1. Jorenby DE, Hays JT, Rigotti NA, et al. Efficacy of varenicline, an a4B2 nicotinic acetylcholine receptor partial agonist, vs placebo or sustained-release bupropion for smoking cessation. JAMA 2006;296:56–63
    1. Oncken C, Gonzalez D, Nides M, et al. Efficacy and safety of the novel selective nicotinic acetylcholine receptor partial agonist varenicline, for smoking cessation. Arch Intern Med 2006;166:1571–7
    1. Tonstad S, Tonnesen P, Hajek P, et al. Effect of maintenance therapy with varenicline on smoking cessation: a randomized controlled trial. JAMA 2006;296:64–71
    1. Kuehn BM. FDA warns of adverse events linked to smoking cessation drug and antileptics. JAMA 2008;299:1121–2
    1. US Department of Health and Human Services The health benefits of smoking cessation: a report of the Surgeon General Rockville, MD: US Government Printing Office, 1990; DHHS Publ No: (CDC) 90-8416
    1. Lamberg L. Patients need more help to quit smoking: counseling and pharmacotherapy double success rate. JAMA 2004;292:1286–90
    1. Silagy C, Lancaster T, Stead L, et al. Nicotine replacement therapy for smoking cessation. Cochrane Database Syst Rev 2004;(3):CD000146
    1. Hughes JR, Shiffman S, Callas P, et al. A meta-analysis of the efficacy of over-the-counter nicotine replacement. Tob Control 2003;2:21–7
    1. Hughes JR, Stead LF, Lancaster T. Antidepressants for smoking cessation. Cochrane Database Syst Rev 2007;(4):CD000031
    1. Hey K, Ussher MH, Lancaster T. Cannabinoid type 1 receptor antagonists (rimonabant) for smoking cessation (protocol). Cochrane Database Systemc Rev 2005;(3):CD005353
    1. Comparison of the efficacy and safety of 2 oral doses of Rimonabant, 5 mg/day or 20 mg/day, versus placebo, as an aid to smoking cessation (STRATUS-US) identifier: NCT00358228. .
    1. Anthenelli R. Rimonabant in smoking abstinence: the STRATUS-program. Society for Research on Nicotine and Tobacco (SNRT) Annual Meeting and 7th Annual European Conference, 20–23 March 2005, Prague, Czech Republic (Presentation).
    1. Gourlay SG, Stead LF, Benowitz NL. Clonidine for smoking cessation. Cochrane Database Syst Rev 2004;(3):CD000058
    1. Hughes JR, Stead LF, Lancaster T. Anxiolytics for smoking cessation. Cochrane Database Syst Rev 2000;(4):CD002849
    1. Lancaster T, Stead LF. Silver acetate for smoking cessation. Cochrane Database Systemc Rev 1997;(3):CD000191
    1. Stead LF, Hughes JR. Lobeline for smoking cessation. Cochrane Database Syst Rev 1997;(3):CD000124
    1. Lancaster T, Stead LF. Mecamylamine (a nicotine antagonist) for smoking cessation. Cochrane Database Syst Rev 1998;(2):CD001009
    1. Lancaster DS, Stead LF, Evins AE. Opioid antagonists for smoking cessation. Cochrane Database Syst Rev 2006;(4):CD003086
    1. Cahill K, Stead LF, Lancaster T. Nicotine receptor partial agonists for smoking cessation. Cochrane Database System Rev 2008;(3):CD006103
    1. Stapleton JA, Watson L, Spirling LI, et al. Varenicline in the routine treatment of tobacco dependence: a pre-post comparison with nicotine replacement therapy and an evaluation in those with mental illness. Addiction 2007;103:146–54
    1. Morstad AE, Kutscher EC, Kennedy WK, et al. Hypomania with agitation associated with varenicline use in bipolar II disorder. Ann Pharmacother 2008;42:288–9
    1. Popkin MK. Exacerbation of recurrent depression as a result of treatment with varenicline. Am J Psychiatry 2008;165:774.
    1. Pumariega AJ, Nelson R, Rotenberg L. Varenicline-induced mixed mood and psychotic episode in a patient with a past history of depression. CNS Spectr 2008;13:511–4
    1. Freedman R. Exacerbation of schizophrenia by varenicline. Am J Psychiatry 2007;164:1269.
    1. Kohen I, Kremen N. Varenicline-induced manic episode in a patient with bipolar disorder. Am J Psychiatry 2007;164:1269–70
    1. Hughes JR. Smoking and suicide: a brief overview. Drug Alcohol Depend. 2008;Aug 1. Epub ahead of print.
    1. Fiore MC, Jaén CR, Baker TB, et al. Treating tobacco use and dependence: 2008 update Rockville, MD: US Department of Health and Human Services, 2008; Available at
    1. LeFoll BL, George TP. Treatment of tobacco dependence: integrating recent progress into practice. CMAJ 2007;177:1373–80
    1. Croghan IT, Hurt RD, Shaker R, et al. Randomized comparison of a nicotine inhaler and bupropion for smoking cessation and relapse prevention. Mayo Clin Proc 2007;82:186–95
    1. Hughes JR, Goldstein MG, Hurt RD, et al. Recent advances in the pharmacotherapy of smoking. JAMA 1999:281:72–6
    1. Powell C. The Delphi technique: myths and realities. J Adv Nurs 2002;41:376–82
    1. Jones J, Hunter D. Using the Delphi and nominal group technique in health services research. Pope C, Mays N, eds. Qualitative research in health care London: BMJ Books, 2000:40–9
    1. Rowe G, Wright G. Expert opinions in forecasting: the role of the Delphi technique. In Armstrong JS, ed. Principles of forecasting. Norwell, MA: Kluwer Academic Publishers, 2000;125–144.
    1. Jones J, Hunter D. Consensus methods for medical and health services research. BMJ 1995;311:376–80
    1. Bader P, Travis H, Skinner HA. Knowledge synthesis of smoking cessation among employed and unemployed young adults. Am J Public Health 2007;97:1434–43
    1. Norman GR, Streiner DL. Biostatistics: the bare essentials Toronto: Mosby, 1994:179–81
    1. Gorsuch RL. Factor analysis Hillsdale, NJ: Laurence Erlbaum, 1983
    1. Selby P. Smoking cessation . In:Gray J, ed. Therapeutic choices, 5th ed. Ottawa, Ontario: Canadian Pharmacist Association, 2007
    1. Hughes J. An algorithm for choosing among smoking cessation treatments. J Subst Abuse Treat 2008;34:426–32
    1. Daar AS, Singer PA, Persad DL, et al. Grand challenges in chronic non-communicable diseases. Nature 2007;450:494–6
    1. Fish LS, Busby DM. The Delphi method. Sprenkle DH, ed. Research methods in family therapy New York: Guilford Press, 1996
    1. Warner KE. Tobacco control policy: from action to evidence and back again. Am J Prev Med 2001;20:2–5

Source: PubMed

Sponsoren und Mitarbeiter

Krankheiten

Drogeninterventionen

3
Abonnieren